Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
vaccine
|
| gptkbp:age |
18 years and above
|
| gptkbp:approvedBy |
January 2021
|
| gptkbp:boosterDoseApproved |
Yes
|
| gptkbp:brand |
gptkb:Covaxin
|
| gptkbp:clinicalTrialPhase |
Phase 3
|
| gptkbp:collaboratedWith |
gptkb:National_Institute_of_Virology
gptkb:Indian_Council_of_Medical_Research |
| gptkbp:countryOfOrigin |
gptkb:India
|
| gptkbp:developedBy |
gptkb:Bharat_Biotech
|
| gptkbp:dosesRequired |
2
|
| gptkbp:effect |
77.8% (against symptomatic COVID-19)
|
| gptkbp:emergencyServices |
gptkb:India
gptkb:World_Health_Organization |
| https://www.w3.org/2000/01/rdf-schema#label |
Covaxin
|
| gptkbp:marketedAs |
gptkb:Bharat_Biotech
|
| gptkbp:routeOfAdministration |
intramuscular
|
| gptkbp:storage |
2-8°C
|
| gptkbp:target |
gptkb:COVID-19
|
| gptkbp:type |
inactivated virus vaccine
|
| gptkbp:WHOListing |
gptkb:Emergency_Use_Listing_(EUL)
|
| gptkbp:bfsParent |
gptkb:COVID-19
gptkb:COVID-19_pandemic |
| gptkbp:bfsLayer |
4
|